This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
11 May 2011

Immunologix & DavosPharma Form Marketing Alliance

The partnership allows both parties to offer their clients a platform to 100% human monoclonal antibody ready for clinical trials.

Immunologix and DavosPharma have established a strategic marketing alliance. According to the agreement achieved, Chemistry services provider DavosPharma will distribute and market 100% antibodies produced by US-based Immunologix.

 

Immunologix specialises in transforming naive B-cells to produce 100% human monoclonal antibodies that can target all antigens, including cancer, viruses, bacteria, toxins and auto-immune diseases such as diabetes, lupus, rheumatoid arthritis and multiple sclerosis.

 

The company collects patient-consented tonsil tissue following tonsillectomies and processes them in its laboratory at the SCRA Innovation Center in Charleston, South Carolina. The company holds a worldwide exclusive licence from the Medical University of South Carolina, and exclusive

Related News